abstract: Clinical effects of @entity800 ( @entity19001 ) in the treatment of @entity7566 was compared with those in the treatment of @entity7566 . @entity11739 was isolated from 33 (39.3%) out of 84 @entity1 with @entity6369 . @entity19001 was administered at a dose of 100 mg, three times daily (300 mg) for 14 days. In 31 (93.3%) of the 33 @entity1 with @entity7566 , @entity11739 was eliminated within 7 to 14 days after the start of administration, and, in two @entity1 , inclusion bodies decreased in number but persisted. The subjective and objective clinical symptoms, urethral discharge, polymorphonuclear leucocyte (PMNL) in smears, and @entity4658 in VB1 of the @entity1 with @entity7566 , disappeared in 56.0, 57.6, and 63.0% of the cases, and improved in 24.0, 30.0 and 29.6% respectively, whereas those of the @entity1 with @entity7566 , urethral discharge, PMNL, and @entity4658 in VB1 disappeared in 57.6, 56.9 and 32.9%, and improved in 26.9, 13.7 and 37.9%, respectively. There was no significant difference in the clinical effects of @entity19001 between cases of @entity7566 and those of @entity7566 . Marked improvement in clinical symptoms were observed between day 7 and day 14 of medication in cases of both chlamydial and @entity7566 . In nine out of 11 cases of @entity7566 where @entity19001 was ineffective, no Ureaplasma nor aerobes, nor @entity11739 , were isolated. In the remaining two cases where Ureaplasma and @entity5938 were isolated respectively, these two bacteria were eradicated after medication, but urethral discharge and PMNL remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Treatment of XXXX --studies on clinical effects of @entity800 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity7566 :: ('MESH:D061387', 'Disease') :: ['chlamydial urethritis', 'non-chlamydial urethritis']

entities_list: @entity6369 :: ('MESH:D014526', 'Disease') :: ['nongonococcal urethritis']

entities_list: @entity5938 :: ('1282', 'Species') :: ['S. epidermidis']

entities_list: @entity11739 :: ('813', 'Species') :: ['Chlamydia trachomatis', 'C. trachomatis']

entities_list: @entity800 :: ('MESH:D015242', 'Chemical') :: ['ofloxacin']

answer: @entity6369 :: (MESH:D014526,Disease) :: ['nongonococcal urethritis']


abstract: Clinical effects of @entity800 ( @entity19001 ) in the treatment of @entity7566 was compared with those in the treatment of @entity7566 . @entity11739 was isolated from 33 (39.3%) out of 84 @entity1 with @entity6369 . @entity19001 was administered at a dose of 100 mg, three times daily (300 mg) for 14 days. In 31 (93.3%) of the 33 @entity1 with @entity7566 , @entity11739 was eliminated within 7 to 14 days after the start of administration, and, in two @entity1 , inclusion bodies decreased in number but persisted. The subjective and objective clinical symptoms, urethral discharge, polymorphonuclear leucocyte (PMNL) in smears, and @entity4658 in VB1 of the @entity1 with @entity7566 , disappeared in 56.0, 57.6, and 63.0% of the cases, and improved in 24.0, 30.0 and 29.6% respectively, whereas those of the @entity1 with @entity7566 , urethral discharge, PMNL, and @entity4658 in VB1 disappeared in 57.6, 56.9 and 32.9%, and improved in 26.9, 13.7 and 37.9%, respectively. There was no significant difference in the clinical effects of @entity19001 between cases of @entity7566 and those of @entity7566 . Marked improvement in clinical symptoms were observed between day 7 and day 14 of medication in cases of both chlamydial and @entity7566 . In nine out of 11 cases of @entity7566 where @entity19001 was ineffective, no Ureaplasma nor aerobes, nor @entity11739 , were isolated. In the remaining two cases where Ureaplasma and @entity5938 were isolated respectively, these two bacteria were eradicated after medication, but urethral discharge and PMNL remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Treatment of @entity6369 --studies on clinical effects of XXXX ].

answer: @entity800 :: (MESH:D015242,Chemical) :: ['ofloxacin']


abstract: OBJECTIVE: Quantitative electroencephalography (qEEG) has been increasingly used to evaluate @entity1 with @entity71 ( @entity71 ). The aim of this study was to assess the correlation between qEEG data and symptom severity in @entity1 with @entity71 . METHODS: Fifteen @entity1 with @entity71 and 20 healthy controls (HCs) were recruited. Electroencephalography was assessed in the resting-state, and qEEG data were obtained in the eyes-closed state. The Korean version of the @entity71 Rating Scale (K-ARS) and continuous performance tests (CPTs) were used to assess all @entity1 . RESULTS: Theta-band (4-7 Hz) power across the brain was significantly positively correlated with inattention scores on the K-ARS, reaction times and commission errors on the CPTs in @entity71 @entity1 . Gamma-band (31-50 Hz) power was significantly positively correlated with the results of the auditory CPTs in @entity71 @entity1 . The theta/alpha (8-12 Hz) and theta/beta (13-30 Hz) ratios were significantly negatively correlated with commission and omission errors on auditory CPTs in @entity71 @entity1 . No significant correlations between qEEG relative power and K-ARS and CPT scores were observed in HCs. CONCLUSION: Our results suggest that qEEG may be a useful adjunctive tool in @entity1 with @entity71 .

title: Quantitative Electroencephalography Reflects Inattention, Visual Error Responses, and Reaction Times in Male XXXX with Attention Deficit Hyperactivity Disorder.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients']

entities_list: @entity71 :: ('MESH:D001289', 'Disease') :: ['attention deficit hyperactivity disorder', 'ADHD']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: Due to the evidence for two distinct steroidogenic cell types in corpora lutea of large domestic animals, cells of the @entity95 corpus luteum were characterized with respect to cell diameters, relative abundance, steroidogenic capacity and responsiveness to hormones. Pseudopregnancy was induced in @entity95 by injection of 30-160 IU pregnant mare's serum gonadotropin (PMSG) followed in 2-4 days by an i.m. injection of 20-35 micrograms @entity1176 ( @entity1176 ). Corpora lutea were obtained 2, 5 and 9 days after injection of @entity1176 and dissociated into single cell suspensions. Suspended steroidogenic cells were incubated (2 h, 37 degrees C) in medium 199 alone or in medium containing ovine luteinizing hormone (oLH) (100 ng/ml), or @entity3044 (100 microM). Media were collected and assayed for @entity1420 content. Secretion of @entity1420 (means +/- SE, n = 4) was stimulated (p less than 0.05) by oLH on each day: Day 2 = 1.7 +/- 0.2-fold; Day 5 = 3.5 +/- 0.4-fold; and Day 9 = 3.1 +/- 0.6-fold stimulation above controls. @entity3044 also stimulated (p less than 0.05) secretion of @entity1420 by suspended luteal cells on Days 2 and 9. Microscopic examination of cell suspensions stained for @entity1816 dehydrogenase (3 beta HSD) activity provided identification of cells with steroidogenic capacity. The diameters (means +/- SE) for steroidogenic cells increased (p less than 0.05) from Days 2 to 9 (Day 2 = 15.2 +/- 0.2 micron; Day 5 = 22.4 +/- 0.4 micron; Day 9 = 28.3 +/- 1.6 micron). The large cell to small cell ratio increased from 0.01 on Day 2 to 2.03 on Day 9.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Size distribution and hormonal responsiveness of dispersed XXXX luteal cells during pseudopregnancy.

entities_list: @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone']

entities_list: @entity1816 :: ('CHEBI:36836', 'Chemical') :: ['3 beta-hydroxysteroid']

entities_list: @entity95 :: ('9986', 'Species') :: ['rabbit', 'New Zealand rabbits']

entities_list: @entity1176 :: ('MESH:D007987', 'Chemical') :: ['GnRH', 'gonadotropin-releasing hormone']

entities_list: @entity3044 :: ('MESH:D007545', 'Chemical') :: ['Isoproterenol', 'isoproterenol']

answer: @entity95 :: (9986,Species) :: ['rabbit']


abstract: BACKGROUND: Although @entity294 is a preventable disease, it remains the second leading cause of @entity204 (after @entity55 ) among @entity1 aged under five years worldwide. The World Health Organization (WHO) scale, the Gorelick scale, and the Clinical Dehydration Scale (CDS) were created to estimate @entity2700 status using clinical signs. The purpose of this study is to determine whether these clinical scales can accurately assess @entity2700 status of @entity1 in a developing country of Kosovo. METHODOLOGY: @entity1 aged 1 month to 5 years with a history of acute @entity294 were enrolled in the study. After recording the data about the @entity1 historical features the treating physician recorded the physical examination findings consistent with each clinical score. Receiver operating characteristic (ROC) curves were constructed to evaluate the performance of the three scales, compared to the gold standard, percent weight change with rehydration. Sensitivity, specificity and likelihood ratios were calculated using the best cut-off points of the ROC curves. RESULTS: We enrolled 230 @entity1 , and 200 @entity1 met eligibility criteria. The WHO scale for predicting significant @entity2700 (>= 5 percent weight change) had an area under the curve (AUC) of 0.71 (95% : CI= 0.65-0.77). The Gorelick scales 4- and 10-point for predicting significant @entity2700 , had an area under the curve of 0.71 (95% : CI=0.63- 0.78) and 0.74 (95% : CI= 0.68-0.81) respectively. Only the CDS for predicting the significant @entity2700 above >= 6% percent weight change, did not have an area under the curve statistically different from the reference line with an AUC of 0.54 (95% CI = 0.45- 0.63). CONCLUSION: The WHO @entity2700 scale and Gorelick scales were fair predictors of @entity2700 in @entity1 with @entity294 . Only the Clinical Dehydration Scale was found not to be a helpful predictor of @entity2700 in our study cohort.

title: Comparing the Accuracy of the Three Dehydration Scales in @entity1 with Acute XXXX in a Developing Country of Kosovo.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children']

entities_list: @entity2700 :: ('MESH:D003681', 'Disease') :: ['dehydration']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

answer: @entity294 :: (MESH:D003967,Disease) :: ['Diarrhea']


abstract: BACKGROUND: Although @entity294 is a preventable disease, it remains the second leading cause of @entity204 (after @entity55 ) among @entity1 aged under five years worldwide. The World Health Organization (WHO) scale, the Gorelick scale, and the Clinical Dehydration Scale (CDS) were created to estimate @entity2700 status using clinical signs. The purpose of this study is to determine whether these clinical scales can accurately assess @entity2700 status of @entity1 in a developing country of Kosovo. METHODOLOGY: @entity1 aged 1 month to 5 years with a history of acute @entity294 were enrolled in the study. After recording the data about the @entity1 historical features the treating physician recorded the physical examination findings consistent with each clinical score. Receiver operating characteristic (ROC) curves were constructed to evaluate the performance of the three scales, compared to the gold standard, percent weight change with rehydration. Sensitivity, specificity and likelihood ratios were calculated using the best cut-off points of the ROC curves. RESULTS: We enrolled 230 @entity1 , and 200 @entity1 met eligibility criteria. The WHO scale for predicting significant @entity2700 (>= 5 percent weight change) had an area under the curve (AUC) of 0.71 (95% : CI= 0.65-0.77). The Gorelick scales 4- and 10-point for predicting significant @entity2700 , had an area under the curve of 0.71 (95% : CI=0.63- 0.78) and 0.74 (95% : CI= 0.68-0.81) respectively. Only the CDS for predicting the significant @entity2700 above >= 6% percent weight change, did not have an area under the curve statistically different from the reference line with an AUC of 0.54 (95% CI = 0.45- 0.63). CONCLUSION: The WHO @entity2700 scale and Gorelick scales were fair predictors of @entity2700 in @entity1 with @entity294 . Only the Clinical Dehydration Scale was found not to be a helpful predictor of @entity2700 in our study cohort.

title: Comparing the Accuracy of the Three Dehydration Scales in XXXX with Acute @entity294 in a Developing Country of Kosovo.

answer: @entity1 :: (9606,Species) :: ['Children']


abstract: INTRODUCTION: @entity65 is the commonest cause of mortality worldwide. Many risk factors predate the development of @entity65 . Adequate knowledge of risk factors for @entity65 is the first step towards effective preventive strategies to combat the @entity65 burden in any population. This study aims to determine the knowledge of workers in a Nigerian University on risk factors for @entity65 . MATERIALS AND METHODS: A cross-sectional survey of 206 academic and non-academic staff of Ladoke Akintola University of Technology, Ogbomoso, Nigeria using the Heart Disease Fact Questionnaire (HDFQ). Demographic data were taken. The lipid profile and random blood sugar were taken. Statistical analysis was done using SPSS 17.0. RESULTS: The mean age of the study @entity1 was 45.3    7.9 years. There were 96 males (46.6%). The mean HDFQ score was 48.6%. Only 41 (19.9%) of @entity1 were assessed to have good knowledge of @entity299 risk factors. Majority, 101 (49.0%) had poor knowledge while 64 (31.2%) had fair knowledge of @entity299 risk factors. There was no significant difference between prevalence of CV risk factors between those with good or fair or low level of knowledge. Most @entity1 did not have a good level of knowledge about risk factors, prevention, treatment and association with @entity6 as it relates to @entity299 . CONCLUSION: Knowledge of @entity299 risk factors is low among University workers in Nigeria. Effective education on @entity299 risk factors and appropriate preventive strategies are indeed important to reduce @entity65 burden in Nigerian University communities.

title: Knowledge of XXXX risk factors among workers in a Nigerian University: A call for concern.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['Cardiovascular disease', 'cardiovascular disease', 'cardiovascular diseases']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['heart diseases', 'heart disease']

answer: @entity299 :: (MESH:D006331,Disease) :: ['heart disease']


abstract: @entity30021 , a new anthracycline antibiotic, was used to treat 24 adult @entity1 with @entity1778 , using a total dose of 300 mg/m2 (75 mg/m2/day X 4). There were 20 @entity1 with acute myelogenous and four with @entity981 . Approximately two-thirds of the @entity1 had a Karnofsky score of less than or equal to 2, and two-thirds had received two or more previous induction programs. Interim bone marrow evaluation was obtained in 18 of 30 remission induction courses and revealed marked hypocellularity in 14, inadequate specimens in three, and persistent disease in one. Seven @entity1 received more than one course. Two @entity1 refused further therapy. In @entity1 with @entity2800 , there were two complete remissions lasting 10 and 16 months and one partial remission lasting 4 1/2 months. There were no responders in @entity1 with @entity981 . @entity137 included profound @entity1431 and @entity882 , moderate @entity390 and @entity391 , @entity294 , and @entity33 . There were no cardiac symptoms associated with the drug infusion, but there were three late events possibly associated with @entity4349 @entity1370 . Used in this dosage schedule, @entity30021 is an active, but toxic, agent in the @entity3052 .

title: Phase II evaluation of XXXX in refractory adult @entity3052 : a Southwest Oncology Group Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['lymphoblastic leukemia', 'acute lymphoblastic leukemia']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity30021 :: ('MESH:D015250', 'Chemical') :: ['Aclarubicin', 'aclarubicin']

entities_list: @entity4349 :: ('CHEBI:48120', 'Chemical') :: ['anthracycline']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis']

entities_list: @entity2800 :: ('MESH:D007951', 'Disease') :: ['myelogenous leukemia']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myelogenous leukemias']

entities_list: @entity1778 :: ('MESH:D007938', 'Disease') :: ['refractory adult leukemia']

entities_list: @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia']

entities_list: @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiotoxicity']

answer: @entity30021 :: (MESH:D015250,Chemical) :: ['aclarubicin']


abstract: @entity30021 , a new anthracycline antibiotic, was used to treat 24 adult @entity1 with @entity1778 , using a total dose of 300 mg/m2 (75 mg/m2/day X 4). There were 20 @entity1 with acute myelogenous and four with @entity981 . Approximately two-thirds of the @entity1 had a Karnofsky score of less than or equal to 2, and two-thirds had received two or more previous induction programs. Interim bone marrow evaluation was obtained in 18 of 30 remission induction courses and revealed marked hypocellularity in 14, inadequate specimens in three, and persistent disease in one. Seven @entity1 received more than one course. Two @entity1 refused further therapy. In @entity1 with @entity2800 , there were two complete remissions lasting 10 and 16 months and one partial remission lasting 4 1/2 months. There were no responders in @entity1 with @entity981 . @entity137 included profound @entity1431 and @entity882 , moderate @entity390 and @entity391 , @entity294 , and @entity33 . There were no cardiac symptoms associated with the drug infusion, but there were three late events possibly associated with @entity4349 @entity1370 . Used in this dosage schedule, @entity30021 is an active, but toxic, agent in the @entity3052 .

title: Phase II evaluation of @entity30021 in refractory adult XXXX : a Southwest Oncology Group Study.

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

answer: @entity3052 :: (MESH:D015470,Disease) :: ['acute leukemia']


abstract: UNASSIGNED: We have previously found high incidence of @entity29 ( @entity29 ) in Australia. A population-based registry was established to assess disease severity, frequency of complications and prognostic factors. METHOD: Incident cases were prospectively identified over 4 years. Early disease severity was assessed according to need for hospitalization and resective surgery and medication use. RESULTS: We report on the early outcomes (median 18 months, range 12-60 months) for 252 @entity1 comprising 146 with @entity30 ( @entity30 ), 96 with @entity31 ( @entity31 ) and 10 IBDU ( @entity29 undifferentiated). 87% of @entity30 @entity1 had @entity32 at diagnosis, and this reduced to 73% at 5 years (n=38). Immunomodulators (IM) were prescribed in 57% of @entity30 @entity1 , and 19% with @entity31 . A third of all @entity30 @entity1 were hospitalised, the majority (77%) in the first 12 months. Risk factors for hospitalisation included penetrating, perianal and @entity66 (p<0.05). 24% of @entity31 @entity1 were hospitalized, most within the first 12 months. Intestinal resection rates were 13% at 1 year in @entity30 , and 26% at 5 years. Risk factors include penetrating and stricturing disease (p<0.001), and ileal involvement (p<0.05). Colectomy rates in @entity31 were 2% and 13% at 1 and 5 years. High CRP at diagnosis was associated with colectomy. CONCLUSION: A high rate of @entity32 , frequent IM use in @entity30 and a low rate of surgery in both @entity30 and @entity31 were identified. In @entity30 , ileal involvement and complex disease behaviour are associated with a more severe disease course; while in @entity31 a high CRP predicted this outcome.

title: A Prospective Population Based Cohort of XXXX in the Biologics era - Disease Course and Predictors of Severity.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory disease']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['ileocolonic disease']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['UC', 'Ulcerative colitis']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'IBD']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ['CD', "Crohn's disease"]

answer: @entity29 :: (MESH:D015212,Disease) :: ['Inflammatory Bowel Disease']


abstract: CONTEXT: Postprandial @entity412 (TG) concentration is independently associated with @entity65 risk. Exercise reduces postprandial TG concentrations, but the mechanisms responsible are unclear. OBJECTIVE: The objective was to determine the effects of exercise on affinity of chylomicrons, large very low-density lipoproteins (VLDL1), and smaller VLDL (VLDL2) for @entity5523 ( @entity5523 )-mediated TG hydrolysis. DESIGN: This was designed as a within- @entity1 crossover study. SETTING: The setting was a university metabolic investigation unit. @entity1 : @entity1 were 10 overweight/obese @entity1 . INTERVENTIONS: @entity1 undertook two oral fat tolerance tests, separated by 7-14 days, in which they had blood taken while fasting and for 4 hours after a high-fat mixed meal. On the afternoon before one test, they performed a 90-minute treadmill walk at 50% maximal @entity26 uptake (exercise trial [EX]); no exercise was performed before the control trial (CON). MAIN OUTCOME MEASURES: We measured circulating TG-rich lipoprotein concentrations and affinity of chylomicrons, VLDL1, and VLDL2 for @entity5523 -mediated TG hydrolysis. RESULTS: Exercise significantly reduced fasting VLDL1-TG concentration (CON, 0.49 [0.33-0.72] mmol.L(-1); EX, 0.36 [0.22-0.59] mmol.L(-1); geometric means [95% confidence interval]; P = .04). Time-averaged postprandial chylomicron-TG (CON, 0.55    0.10 mmol.L(-1); EX, 0.39    0.08 mmol.L(-1); mean    SEM; P = .03) and VLDL1-TG (CON, 0.85    0.13 mmol.L(-1); EX, 0.66    0.10 mmol.L(-1); P = .01) concentrations were both lower in EX than CON. Affinity of VLDL1 for @entity5523 -mediated TG hydrolysis increased by 2.2 (1.3-3.7)-fold [geometric mean (95% confidence interval)] (P = .02) in the fasted state and 2.6 (1.8-2.6)-fold (P = .001) postprandially. Affinity of chylomicrons and VLDL2 was not significantly different between trials. CONCLUSIONS: Exercise increases affinity of VLDL1 for @entity5523 -mediated TG hydrolysis both fasting and postprandially. This mechanism is likely to contribute to the TG-lowering effect of exercise.

title: Moderate Exercise Increases Affinity of Large Very Low-Density Lipoproteins for Hydrolysis by XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participant', 'Participants', 'PARTICIPANTS', 'men']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity5523 :: ('4023', 'Gene') :: ['LPL', 'lipoprotein lipase']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

answer: @entity5523 :: (4023,Gene) :: ['Lipoprotein Lipase']


abstract: @entity1 with @entity5345 mutations are inundated with decisions about managing @entity5 risks and childbearing considerations. Decisions become more complicated when @entity1 face disclosing their mutation and risk-reduction options to a romantic partner. This study identifies the concerns and perspectives of male romantic partners regarding these unique decisions. Twenty-five male @entity1 completed an online survey posted to @entity5 support group message boards. @entity1 reported relationship changes regarding intimacy levels (n   =   9), attraction (n   =   2), and communication (n   =   22) after mutation disclosure. @entity1 whose partners had not undergone prophylactic mastectomy (n   =   14) reported concerns regarding sexual relations (n   =   5), post-surgical appearance (n   =   2), post-surgical attraction (n   =   5), and health/lifespan (n   =   9). @entity1 did not express attitude changes toward childbearing. While mutation disclosure conversations and surgical options are concerns for many @entity5345 mutation carriers in relationships, male partners share these concerns. Aspects of the relationship may change, but male study @entity1 continued to support their partners. This information can benefit female @entity5345 mutation carriers, their current or future partners, and genetic counselors working with this particular population.

title: Exploration of Male Attitudes on Partnerships and Sexuality with Female XXXX /2 Mutation Carriers.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'Women', 'Participants']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

answer: @entity5345 :: (672,Gene) :: ['BRCA1']


abstract: UNASSIGNED: An improvement in bond strength to enamel has been demonstrated with the use of @entity8718 prior to bonding with self-etch @entity11379 -based adhesive agents. No research has evaluated the effect of @entity8718 etching of enamel with a newer self-etch @entity16971 adhesive. The purpose of this study was to evaluate the shear-bond strength of composite to enamel using the self-etch @entity16971 adhesive compared to other self-etching @entity11379 -based adhesives, with or without a separate application of @entity8718 . @entity291 incisors were sectioned using a @entity11710 saw and mounted in plastic pipe. The bonding agents were applied to flattened enamel surfaces with or without the application of 35% @entity8718 . The bonded tooth specimens were inserted beneath a mold, and composite was placed incrementally and light cured. The specimens were stored for 24 hours and six months in water and tested in shear. Data were analyzed with a three-way analysis of variance (ANOVA) to evaluate the effects of surface treatment, adhesive agent, or time on the bond strength of composite to @entity291 enamel (a=0.05). Significant differences were found between the groups based on surface treatment (p<0.01) or adhesive agent (p<0.01), but not on time (p=0.19), with no significant interactions (p>0.14). @entity8718 etching of @entity291 enamel significantly increased the bond strength of the self-etch @entity11379 and the @entity16971 adhesives. The @entity11379 -based adhesives had significantly greater bond strength to enamel than the @entity16971 adhesive.

title: Effect of Selective Etch on the Bond Strength of Composite to Enamel Using a XXXX Adhesive.

entities_list: @entity8718 :: ('MESH:C030242', 'Chemical') :: ['Phosphoric-acid', 'phosphoric acid', 'phosphoric-acid']

entities_list: @entity11379 :: ('CHEBI:25218', 'Chemical') :: ['methacrylate']

answer: @entity16971 :: (MESH:D062047,Chemical) :: ['Silorane']


abstract: PURPOSE: We examined the clinical data of @entity1 treated with @entity901 to determine the risk factors of @entity901 -related @entity56 ( @entity56 ). In addition, we evaluated the efficacy of rechallenging @entity1 with HSRs with @entity901 using prophylactic agents or desensitization procedures. METHODS: This study consisted of 162 @entity1 with @entity14 (88 @entity1 and 74 @entity1 ) who were treated consecutively at the outpatient chemotherapy department at University Hospital, Kyoto Prefectural University of Medicine. @entity1 underwent chemotherapy, including @entity901 , between March 2006 and June 2012. We analyzed the @entity1 ' clinical backgrounds (eg, age, sex, performance status, disease stage, and allergic history) to uncover any connections to the development of @entity56 to @entity901 . In addition, we rechallenged 10 @entity1 who had @entity901 -related @entity56 using prophylactic agents or desensitization procedures. FINDINGS: Of 162 @entity1 , 28 (17.2%) developed @entity901 -related HSRs (16, 2, 9 and 1 @entity1 had grade 1, 2, 3, and 4 HSRs, respectively). The total cumulative dose of @entity901 at the onset of the @entity56 was 301 to 1126 mg/m(2) (median, 582 mg/m(2)), and the first reactions developed in these @entity1 after 5 to 17 infusions of @entity901 (median, 8 infusions). Logistic regression analysis indicated that sex (male: odds ratio = 3.624; 95% CI, 1.181-11.122; P = 0.024) and eosinophil count in peripheral blood (odds ratio = 35.118; 95% CI, 1.058-1166.007; P = 0.046) were independent variables for @entity901 -related HSRs. Rechallenging @entity1 with prophylactic agents was successful in 2 (28.6%) of 7 @entity1 who successfully completed their treatment. On the other hand, all 3 @entity1 rechallenged with @entity901 using a desensitization protocol successfully completed their treatment without new HSRs. IMPLICATIONS: In this retrospective study, we observed that being male and having higher counts of peripheral eosinophil could be predictors for @entity56 to @entity901 . In addition, this study confirms that @entity901 desensitization protocol allows @entity1 who developed HSRs to continue with their treatment. However, the optimum desensitization protocol for @entity901 administration in terms of tolerability and efficacy needs to be defined.

title: XXXX Reactions to @entity901 : Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'patient', 'men']

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['HSR', 'hypersensitivity reaction']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

answer: @entity56 :: (MESH:D004342,Disease) :: ['Hypersensitivity']


abstract: PURPOSE: We examined the clinical data of @entity1 treated with @entity901 to determine the risk factors of @entity901 -related @entity56 ( @entity56 ). In addition, we evaluated the efficacy of rechallenging @entity1 with HSRs with @entity901 using prophylactic agents or desensitization procedures. METHODS: This study consisted of 162 @entity1 with @entity14 (88 @entity1 and 74 @entity1 ) who were treated consecutively at the outpatient chemotherapy department at University Hospital, Kyoto Prefectural University of Medicine. @entity1 underwent chemotherapy, including @entity901 , between March 2006 and June 2012. We analyzed the @entity1 ' clinical backgrounds (eg, age, sex, performance status, disease stage, and allergic history) to uncover any connections to the development of @entity56 to @entity901 . In addition, we rechallenged 10 @entity1 who had @entity901 -related @entity56 using prophylactic agents or desensitization procedures. FINDINGS: Of 162 @entity1 , 28 (17.2%) developed @entity901 -related HSRs (16, 2, 9 and 1 @entity1 had grade 1, 2, 3, and 4 HSRs, respectively). The total cumulative dose of @entity901 at the onset of the @entity56 was 301 to 1126 mg/m(2) (median, 582 mg/m(2)), and the first reactions developed in these @entity1 after 5 to 17 infusions of @entity901 (median, 8 infusions). Logistic regression analysis indicated that sex (male: odds ratio = 3.624; 95% CI, 1.181-11.122; P = 0.024) and eosinophil count in peripheral blood (odds ratio = 35.118; 95% CI, 1.058-1166.007; P = 0.046) were independent variables for @entity901 -related HSRs. Rechallenging @entity1 with prophylactic agents was successful in 2 (28.6%) of 7 @entity1 who successfully completed their treatment. On the other hand, all 3 @entity1 rechallenged with @entity901 using a desensitization protocol successfully completed their treatment without new HSRs. IMPLICATIONS: In this retrospective study, we observed that being male and having higher counts of peripheral eosinophil could be predictors for @entity56 to @entity901 . In addition, this study confirms that @entity901 desensitization protocol allows @entity1 who developed HSRs to continue with their treatment. However, the optimum desensitization protocol for @entity901 administration in terms of tolerability and efficacy needs to be defined.

title: @entity56 Reactions to XXXX : Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.

answer: @entity901 :: (MESH:C030110,Chemical) :: ['Oxaliplatin']


abstract: BACKGROUND: Vitiligo is a common @entity272 that can influence a @entity1 's quality of life. Although @entity1 -orientated medicine is an emerging concept, a self-assessment tool to assess the degree of depigmentation in @entity1694 is not yet available. Therefore, we developed the SAVASI, a self-assessment tool that uses the same basic principles as the VASI. OBJECTIVE: To assess the validity, reliability and acceptability of the SAVASI. METHODS: To assess the validity of the SAVASI, we compared the scores assessed by the @entity1 with the scores of the VASI assessed by the physician. To assess the intra-rater reliability, the correlation between the baseline SAVASI and the SAVASI after 2  weeks was calculated. To assess the acceptability, @entity1 indicated the time needed to complete the SAVASI and the @entity1 assessed the difficulty of the questionnaire on a five-point scale. The Skindex-29 was used to determine the quality of life. The overestimation of the SAVASI compared to the VASI was calculated by subtracting the VASI scores off from the SAVASI scores. RESULTS: A high correlation between the VASI and the SAVASI (ICC 0.97, 95% CI: 0.95-0.98) was found in 60 @entity1 . The intra-rater reliability of the SAVASI (ICC 0.75, 95% CI 0.54-0.87) was adequate in 31 @entity1 . Fifty (83%) of the @entity1 completed the questionnaire within 10  min and only five (8%) of the @entity1 considered the SAVASI hard. We found no correlation between overestimation of the SAVASI score and the Skindex-29 score. CONCLUSION: The SAVASI is a valid, reliable and acceptable self-assessment tool to measure the degree of depigmentation in @entity1694 . With the SAVASI the degree of depigmentation can reliably be assessed by the @entity1 themselves which can be useful in large (epidemiological) studies. Furthermore, this could contribute to the @entity1 's disease insight and therapy loyalty.

title: The validity, reliability and acceptability of the SAVASI; a new self-assessment score in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['depigmenting skin disorder']

answer: @entity1694 :: (MESH:D014820,Disease) :: ['vitiligo']


abstract: BACKGROUND: Anesthetic management for cesarean section of @entity1 with @entity5030 accreta is challenging. The aim of this retrospective study was to review past @entity5030 accreta cases in our hospital to propose a better strategy for anesthetic management for this difficult condition. METHODS: Cases of @entity5030 accreta were identified in our anesthesia database. The diagnosis, surgical procedure, amount of @entity190 and anesthetic management were reviewed. RESULTS: Eight cases of @entity5030 accreta were identified. Four of the eight cases underwent stepwise treatment, and in one of the four cases, @entity432 ( @entity432 ) was performed. The amount of @entity190 in the four cases ranged from 840 to 1,150 ml. The remaining four cases underwent cesarean hysterectomy. The amount of @entity190 in the four cases ranged from 2,400 to 5,200 ml. Neuraxial anesthesia alone was planned in four cases, but in two of which anesthesia was converted to general anesthesia due to @entity548 . CONCLUSIONS: The present retrospective study showed that stepwise treatment and using @entity432 could be an effective aid for management of plasenta previa accreta. It is necessary to compare the effectiveness of @entity432 with that of common iliac @entity432 in reducing the amount of @entity190 .

title: [Anesthetic management of @entity1 with XXXX accreta for cesarean section: a 7-year single-center experience].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['massive bleeding']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity5030 :: ('MESH:D010923', 'Disease') :: ['placenta previa']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['artery occlusion', 'IABO', 'intra-aortic balloon occlusion']

answer: @entity5030 :: (MESH:D010923,Disease) :: ['placenta previa']


abstract: BACKGROUND: Anesthetic management for cesarean section of @entity1 with @entity5030 accreta is challenging. The aim of this retrospective study was to review past @entity5030 accreta cases in our hospital to propose a better strategy for anesthetic management for this difficult condition. METHODS: Cases of @entity5030 accreta were identified in our anesthesia database. The diagnosis, surgical procedure, amount of @entity190 and anesthetic management were reviewed. RESULTS: Eight cases of @entity5030 accreta were identified. Four of the eight cases underwent stepwise treatment, and in one of the four cases, @entity432 ( @entity432 ) was performed. The amount of @entity190 in the four cases ranged from 840 to 1,150 ml. The remaining four cases underwent cesarean hysterectomy. The amount of @entity190 in the four cases ranged from 2,400 to 5,200 ml. Neuraxial anesthesia alone was planned in four cases, but in two of which anesthesia was converted to general anesthesia due to @entity548 . CONCLUSIONS: The present retrospective study showed that stepwise treatment and using @entity432 could be an effective aid for management of plasenta previa accreta. It is necessary to compare the effectiveness of @entity432 with that of common iliac @entity432 in reducing the amount of @entity190 .

title: [Anesthetic management of XXXX with @entity5030 accreta for cesarean section: a 7-year single-center experience].

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: When @entity1 polymorphonuclear leukocytes (PMN) are placed on various surfaces, they attach and spread rapidly, increasing their diameter severalfold. The spreading is associated with extensive changes in the cytoskeleton. Since many cytoskeletal events are regulated by @entity141 , we measured the cytosolic free @entity460 concentration ([ @entity141 ]i) in individual @entity1 PMN as they spread. [ @entity141 ]i was measured in single cells by microspectrofluorometry using the fluorescent @entity141 -sensitive dye @entity593 . Immediately before spreading, PMN exhibit a rapid increase in [ @entity141 ]i, from 69 +/- 51 nM to 547 +/- 190 nM (mean +/- SD, n = 12). [ @entity141 ]i returns to near resting levels during the next minute, as the cells spread. Neither the spreading nor the [ @entity141 ]i spike is blocked by removal of extracellular @entity460 , by @entity1855 , by calmodulin antagonists, or by mitochondrial or microtubule poisons. Spreading, but not the [ @entity141 ]i increase, is blocked by the microfilament inhibitor cytochalasin B. Both spreading and the [ @entity141 ]i spike are blocked by @entity855 depletion and reversibly blocked by placing the cells in medium containing hypertonic sucrose or @entity2827 . These data strongly suggest that an increase in [ @entity141 ]i, derived from nonmitochondrial intracellular pools, plays an important role in the microfilament-mediated process of PMN spreading.

title: Spreading of @entity1 neutrophils is immediately preceded by a large increase in cytoplasmic free XXXX .

entities_list: @entity1855 :: ('MESH:D014700', 'Chemical') :: ['verapamil']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity2827 :: ('MESH:D012965', 'Chemical') :: ['sodium chloride']

answer: @entity460 :: (MESH:D002118,Chemical) :: ['calcium']


abstract: When @entity1 polymorphonuclear leukocytes (PMN) are placed on various surfaces, they attach and spread rapidly, increasing their diameter severalfold. The spreading is associated with extensive changes in the cytoskeleton. Since many cytoskeletal events are regulated by @entity141 , we measured the cytosolic free @entity460 concentration ([ @entity141 ]i) in individual @entity1 PMN as they spread. [ @entity141 ]i was measured in single cells by microspectrofluorometry using the fluorescent @entity141 -sensitive dye @entity593 . Immediately before spreading, PMN exhibit a rapid increase in [ @entity141 ]i, from 69 +/- 51 nM to 547 +/- 190 nM (mean +/- SD, n = 12). [ @entity141 ]i returns to near resting levels during the next minute, as the cells spread. Neither the spreading nor the [ @entity141 ]i spike is blocked by removal of extracellular @entity460 , by @entity1855 , by calmodulin antagonists, or by mitochondrial or microtubule poisons. Spreading, but not the [ @entity141 ]i increase, is blocked by the microfilament inhibitor cytochalasin B. Both spreading and the [ @entity141 ]i spike are blocked by @entity855 depletion and reversibly blocked by placing the cells in medium containing hypertonic sucrose or @entity2827 . These data strongly suggest that an increase in [ @entity141 ]i, derived from nonmitochondrial intracellular pools, plays an important role in the microfilament-mediated process of PMN spreading.

title: Spreading of XXXX neutrophils is immediately preceded by a large increase in cytoplasmic free @entity460 .

answer: @entity1 :: (9606,Species) :: ['human']


abstract: A @entity1 presented with a primary @entity320 , Level IV, 2.5 mm thick; 30 excised lymph nodes were all negative for @entity5 . Four local recurrences followed in the ensuing 17 months. @entity5 cells cultured at this time were epithelioid. Autoimmunization was followed by a disease-free interval of 15 months. Postimmunization, the @entity1 's lymphocytes destroyed his @entity320 cells in culture and were stimulated in mixed cell culture by his irradiated @entity5 cells. Cells grown from the relapsing @entity5 were spindle/dendritic with bizarre morphology and were not attacked by his lymphocytes in culture. Using a C' fixation technique, DR antigen profiles of the @entity1 's B-cells and both @entity5 cell types showed that the immunizing @entity5 was positive for DR antigens 3, 5, and 8, none of which were present on his B-cells which had @entity4107 . Both B-cells and immunizing @entity5 cells were positive for DQ antigens. The relapsing @entity5 cells were positive for DR2 and negative for all other D region antigens tested. The evidence suggests that given a @entity320 of heterogeneous cell population, autoimmunization against the predominant immunogenic cell inhibits @entity5 growth but allows the ascendance of a nonimmunogenic @entity5 cell type.

title: Immunological heterogeneity in @entity1 XXXX : immunogenic alloantigen expression in autologous host.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma']

answer: @entity320 :: (MESH:D008545,Disease) :: ['melanoma']


abstract: A @entity1 presented with a primary @entity320 , Level IV, 2.5 mm thick; 30 excised lymph nodes were all negative for @entity5 . Four local recurrences followed in the ensuing 17 months. @entity5 cells cultured at this time were epithelioid. Autoimmunization was followed by a disease-free interval of 15 months. Postimmunization, the @entity1 's lymphocytes destroyed his @entity320 cells in culture and were stimulated in mixed cell culture by his irradiated @entity5 cells. Cells grown from the relapsing @entity5 were spindle/dendritic with bizarre morphology and were not attacked by his lymphocytes in culture. Using a C' fixation technique, DR antigen profiles of the @entity1 's B-cells and both @entity5 cell types showed that the immunizing @entity5 was positive for DR antigens 3, 5, and 8, none of which were present on his B-cells which had @entity4107 . Both B-cells and immunizing @entity5 cells were positive for DQ antigens. The relapsing @entity5 cells were positive for DR2 and negative for all other D region antigens tested. The evidence suggests that given a @entity320 of heterogeneous cell population, autoimmunization against the predominant immunogenic cell inhibits @entity5 growth but allows the ascendance of a nonimmunogenic @entity5 cell type.

title: Immunological heterogeneity in XXXX @entity320 : immunogenic alloantigen expression in autologous host.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: BACKGROUND: @entity4225 ( @entity4225 ) has been associated with an intensive use of health resources and a high economic burden. AIMS OF THE STUDY: The aim of this study is to analyze the use of mental healthcare resources by @entity4225 @entity1 , to identify the information gaps on @entity4225 at the regional health databases and to describe specific indicators and patterns of care utilization by @entity1 with @entity4225 in order to guide evidence-informed policy planning in Catalonia (Spain). METHODS: A multi-level cross-design synthesis approach was applied following a mixed quantitative-qualitative analysis to estimate the regional service utilisation of @entity1 with @entity4225 . This framing analysis included estimates based on all available data on the use of services combined with prior expert knowledge gathered through a nominal group of key stakeholders in this field. RESULTS: The estimated year prevalence of @entity4225 was 0.7% but only 9.6% of all @entity4225 @entity1 in Catalonia had any contact with the health care system. Of those, less than half contacted mental health care. @entity4225 represented 1.7% of the total care load in the community mental health centres. A significant information gap was identified in all the official databases and impeded their direct use for planning and resource allocation in @entity4225 . Expert knowledge was required to estimate rates of care utilization at every level of care system (primary care, specialized outpatient care and hospital care). Nevertheless the high pattern of care utilization identified at the databases was accurate according to the experts. DISCUSSION: Detection of @entity4225 was lower than expected in the local, regional and national databases and registries of Catalonia. Local data was judged highly inaccurate by experts in comparison to data available on other @entity146 in the same databases. IMPLICATIONS FOR HEALTH POLICY AND RESEARCH: Specific incentives should be implemented to improve the availability and accuracy of information on @entity4225 at the regional databases. When present, @entity4225 should be coded before other @entity146 in clinical records and health databases. Mental health surveys and @entity146 epidemiological studies should specifically incorporate @entity4225 in their inclusion criteria and further studies on the utilisation pattern of this disorder are needed, both locally and internationally.

title: Regional Analysis of Health Service Utilisation by XXXX with Borderline Personality Disorders: Implications for Evidence-Informed Policy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'persons']

entities_list: @entity4225 :: ('MESH:D001883', 'Disease') :: ['BPD', 'Borderline Personality Disorder']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['mental disorders', 'psychiatric', 'psychiatric disorders']

answer: @entity1 :: (9606,Species) :: ['Persons']


abstract: UNASSIGNED: There is still disagreement regarding the intracranial volumes of @entity1 with @entity91 compared with healthy @entity1 . This study aimed to compare the intracranial volume of @entity1 with @entity91 before and after surgery to an age- and sex-matched control cohort using three-dimensional (3D) photogrammetry. Eighteen @entity1 with @entity91 were operated on using standardized fronto-orbital advancement. Frontal, posterior and total intracranial volumes were measured exactly 1 day pre-operatively and 10 days post-operatively, using 3D photogrammetry. To establish an age- and sex-matched control group, the 3D photogrammetric data of 634 healthy @entity1 between the ages of 3 and 13 months were analyzed. Mean age at surgery was 9 months (SD 1.7). Prior to surgery, @entity1 with @entity91 showed significantly reduced frontal and total intracranial volumes compared with the reference group, but similar posterior volumes. After surgery, frontal and total intracranial volumes did not differ statistically from the control group. As @entity1 with @entity91 showed significantly smaller frontal and total intracranial volumes compared with an age- and sex-matched control group, corrective surgery should aim to achieve volume expansion. Furthermore, 3D photogrammetry provides a valuable alternative to CT scans in the measurement of intracranial volume in @entity1 with @entity91 , which significantly reduces the amount of radiation exposure to the growing brain.

title: XXXX : Measuring intracranial volume change following fronto-orbital advancement using three-dimensional photogrammetry.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'children', 'boys']

entities_list: @entity91 :: ('MESH:D003398', 'Disease') :: ['metopic synostosis']

answer: @entity91 :: (MESH:D003398,Disease) :: ['Metopic synostosis']


abstract: OBJECTIVE: Low-volume @entity968 ( @entity970 ) bowel preparations have been developed to improve compliance for colonoscopy. Our study aimed to compare the efficacy and tolerability of low-volume @entity970 containing @entity620 for colonoscopy against 2 L of @entity970 plus @entity15021 . METHODS: We prospectively enrolled consecutive inpatients who had not undergone polypectomy at the index colonoscopy and were subsequently referred for polypectomy at our hospital. A total of 62 @entity1 were randomized to receive either low-volume @entity970 containing @entity620 (n = 31) or 2 L of @entity970 plus @entity15021 (n = 31) as a split-dose regimen in inpatients. The efficacy of preparation was determined using the @entity29 ( @entity29 ) and a 4-point scale. Adverse events, tolerability, and willingness were evaluated using a questionnaire. RESULTS: Based on the @entity29 and 4-point scale, we determined that the efficacy of low-volume @entity970 containing @entity620 was comparable to that of the 2 L of @entity970 plus @entity15021 (p = 0.071 for @entity29 , p = 0.056 for the 4-point scale). Adverse events were comparable between the two groups (p = 1.000). A greater proportion of @entity1 in the low-volume @entity970 containing @entity620 (90.6%) and the 2L of @entity970 plus @entity15021 (96.9%) were willing to repeat the same preparation for subsequent colonoscopy. CONCLUSION: Low-volume @entity970 containing @entity620 had comparable efficacy and tolerability to 2 L of @entity970 plus @entity15021 , when given as a split dose, for colonoscopy in inpatients. Split-dose low-volume @entity970 containing @entity620 is a good alternative for bowel preparation for colonoscopy in inpatients.

title: The use of low-volume @entity968 containing XXXX versus 2 L of @entity968 plus @entity15021 as bowel preparation for colonoscopy.

entities_list: @entity620 :: ('MESH:D001205', 'Chemical') :: ['ascorbic acid']

entities_list: @entity15021 :: ('MESH:D001726', 'Chemical') :: ['bisacodyl']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['Ottawa Bowel Preparation Score', 'OBPS']

entities_list: @entity968 :: ('MESH:D011092', 'Chemical') :: ['polyethylene glycol']

answer: @entity620 :: (MESH:D001205,Chemical) :: ['ascorbic acid']


abstract: OBJECTIVE: Low-volume @entity968 ( @entity970 ) bowel preparations have been developed to improve compliance for colonoscopy. Our study aimed to compare the efficacy and tolerability of low-volume @entity970 containing @entity620 for colonoscopy against 2 L of @entity970 plus @entity15021 . METHODS: We prospectively enrolled consecutive inpatients who had not undergone polypectomy at the index colonoscopy and were subsequently referred for polypectomy at our hospital. A total of 62 @entity1 were randomized to receive either low-volume @entity970 containing @entity620 (n = 31) or 2 L of @entity970 plus @entity15021 (n = 31) as a split-dose regimen in inpatients. The efficacy of preparation was determined using the @entity29 ( @entity29 ) and a 4-point scale. Adverse events, tolerability, and willingness were evaluated using a questionnaire. RESULTS: Based on the @entity29 and 4-point scale, we determined that the efficacy of low-volume @entity970 containing @entity620 was comparable to that of the 2 L of @entity970 plus @entity15021 (p = 0.071 for @entity29 , p = 0.056 for the 4-point scale). Adverse events were comparable between the two groups (p = 1.000). A greater proportion of @entity1 in the low-volume @entity970 containing @entity620 (90.6%) and the 2L of @entity970 plus @entity15021 (96.9%) were willing to repeat the same preparation for subsequent colonoscopy. CONCLUSION: Low-volume @entity970 containing @entity620 had comparable efficacy and tolerability to 2 L of @entity970 plus @entity15021 , when given as a split dose, for colonoscopy in inpatients. Split-dose low-volume @entity970 containing @entity620 is a good alternative for bowel preparation for colonoscopy in inpatients.

title: The use of low-volume XXXX containing @entity620 versus 2 L of @entity968 plus @entity15021 as bowel preparation for colonoscopy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity968 :: (MESH:D011092,Chemical) :: ['polyethylene glycol']


abstract: OBJECTIVE: Low-volume @entity968 ( @entity970 ) bowel preparations have been developed to improve compliance for colonoscopy. Our study aimed to compare the efficacy and tolerability of low-volume @entity970 containing @entity620 for colonoscopy against 2 L of @entity970 plus @entity15021 . METHODS: We prospectively enrolled consecutive inpatients who had not undergone polypectomy at the index colonoscopy and were subsequently referred for polypectomy at our hospital. A total of 62 @entity1 were randomized to receive either low-volume @entity970 containing @entity620 (n = 31) or 2 L of @entity970 plus @entity15021 (n = 31) as a split-dose regimen in inpatients. The efficacy of preparation was determined using the @entity29 ( @entity29 ) and a 4-point scale. Adverse events, tolerability, and willingness were evaluated using a questionnaire. RESULTS: Based on the @entity29 and 4-point scale, we determined that the efficacy of low-volume @entity970 containing @entity620 was comparable to that of the 2 L of @entity970 plus @entity15021 (p = 0.071 for @entity29 , p = 0.056 for the 4-point scale). Adverse events were comparable between the two groups (p = 1.000). A greater proportion of @entity1 in the low-volume @entity970 containing @entity620 (90.6%) and the 2L of @entity970 plus @entity15021 (96.9%) were willing to repeat the same preparation for subsequent colonoscopy. CONCLUSION: Low-volume @entity970 containing @entity620 had comparable efficacy and tolerability to 2 L of @entity970 plus @entity15021 , when given as a split dose, for colonoscopy in inpatients. Split-dose low-volume @entity970 containing @entity620 is a good alternative for bowel preparation for colonoscopy in inpatients.

title: The use of low-volume @entity968 containing @entity620 versus 2 L of XXXX plus @entity15021 as bowel preparation for colonoscopy.

answer: @entity968 :: (MESH:D011092,Chemical) :: ['polyethylene glycol']


abstract: OBJECTIVE: Low-volume @entity968 ( @entity970 ) bowel preparations have been developed to improve compliance for colonoscopy. Our study aimed to compare the efficacy and tolerability of low-volume @entity970 containing @entity620 for colonoscopy against 2 L of @entity970 plus @entity15021 . METHODS: We prospectively enrolled consecutive inpatients who had not undergone polypectomy at the index colonoscopy and were subsequently referred for polypectomy at our hospital. A total of 62 @entity1 were randomized to receive either low-volume @entity970 containing @entity620 (n = 31) or 2 L of @entity970 plus @entity15021 (n = 31) as a split-dose regimen in inpatients. The efficacy of preparation was determined using the @entity29 ( @entity29 ) and a 4-point scale. Adverse events, tolerability, and willingness were evaluated using a questionnaire. RESULTS: Based on the @entity29 and 4-point scale, we determined that the efficacy of low-volume @entity970 containing @entity620 was comparable to that of the 2 L of @entity970 plus @entity15021 (p = 0.071 for @entity29 , p = 0.056 for the 4-point scale). Adverse events were comparable between the two groups (p = 1.000). A greater proportion of @entity1 in the low-volume @entity970 containing @entity620 (90.6%) and the 2L of @entity970 plus @entity15021 (96.9%) were willing to repeat the same preparation for subsequent colonoscopy. CONCLUSION: Low-volume @entity970 containing @entity620 had comparable efficacy and tolerability to 2 L of @entity970 plus @entity15021 , when given as a split dose, for colonoscopy in inpatients. Split-dose low-volume @entity970 containing @entity620 is a good alternative for bowel preparation for colonoscopy in inpatients.

title: The use of low-volume @entity968 containing @entity620 versus 2 L of @entity968 plus XXXX as bowel preparation for colonoscopy.

answer: @entity15021 :: (MESH:D001726,Chemical) :: ['bisacodyl']


abstract: OBJECTIVE: This is the first cohort in which @entity393 and @entity2169 in @entity12697 are described extensively. METHODS: Retrospective analysis of the otorhinolaryngological and clinical genetic data from 97 @entity12697 ( @entity12697 ) @entity1 . Forty-four @entity12697 @entity1 were seen by an otorhinolaryngologist for the analysis of @entity393 . In our cohort 80 of the 97 @entity1 were genetically tested. In 71 of these mutations were found: in 48 @entity1 a mutation in @entity9702 , in 10 @entity1 in @entity25941 , in 5 @entity1 in @entity25281 , in 5 @entity1 in @entity10242 , in 1 @entity1 in @entity29343 , in 1 @entity1 in @entity984 and in 1 @entity1 in @entity29740 . RESULTS: @entity2169 were reported in 75 @entity12697 @entity1 (77%). In 69 @entity1 the ears were low-set, 28 @entity1 had @entity717 , 14 @entity1 showed protruding ears and 18 had thickened helices. Hearing impairment was detected in 34 @entity12697 @entity1 . Nine @entity1 had @entity1274 , two a permanent conductive @entity393 , two other @entity1 had mixed @entity393 and 20 @entity1 had conductive @entity393 in the past, caused by @entity2346 media with effusion. Their temporary conductive @entity393 resolved between the ages of 2 and 18 years. @entity1274 varied between mild @entity2198 and profound (uni- and bilateral) @entity393 and was progressive in three @entity1 . Four @entity12697 @entity1 received cochlear implants for their severe @entity1274 . The cohort is small for genotype-phenotype correlations, but @entity1274 , especially the bilateral severe @entity393 , was only seen in @entity1 with a @entity9702 mutation. CONCLUSION: @entity12697 is characterized by dysmorphic @entity2169 and both @entity1274 . Audiological examinations are recommended in all @entity1 with @entity12697 .

title: @entity2169 and XXXX in @entity12697 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2198 :: ('MESH:D006316', 'Disease') :: ['high-frequency hearing impairment']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['posteriorly rotated ears']

entities_list: @entity1274 :: ('MESH:D006319', 'Disease') :: ['Sensorineural hearing impairment', 'sensorineural and conductive hearing impairment', 'sensorineural hearing impairment']

entities_list: @entity2169 :: ('MESH:D004427', 'Disease') :: ['External ear anomalies', 'external ear anomalies']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing impairment']

entities_list: @entity12697 :: ('MESH:D009634', 'Disease') :: ['Noonan Syndrome', 'NS']

answer: @entity393 :: (MESH:D034381,Disease) :: ['hearing impairment']


abstract: OBJECTIVE: This is the first cohort in which @entity393 and @entity2169 in @entity12697 are described extensively. METHODS: Retrospective analysis of the otorhinolaryngological and clinical genetic data from 97 @entity12697 ( @entity12697 ) @entity1 . Forty-four @entity12697 @entity1 were seen by an otorhinolaryngologist for the analysis of @entity393 . In our cohort 80 of the 97 @entity1 were genetically tested. In 71 of these mutations were found: in 48 @entity1 a mutation in @entity9702 , in 10 @entity1 in @entity25941 , in 5 @entity1 in @entity25281 , in 5 @entity1 in @entity10242 , in 1 @entity1 in @entity29343 , in 1 @entity1 in @entity984 and in 1 @entity1 in @entity29740 . RESULTS: @entity2169 were reported in 75 @entity12697 @entity1 (77%). In 69 @entity1 the ears were low-set, 28 @entity1 had @entity717 , 14 @entity1 showed protruding ears and 18 had thickened helices. Hearing impairment was detected in 34 @entity12697 @entity1 . Nine @entity1 had @entity1274 , two a permanent conductive @entity393 , two other @entity1 had mixed @entity393 and 20 @entity1 had conductive @entity393 in the past, caused by @entity2346 media with effusion. Their temporary conductive @entity393 resolved between the ages of 2 and 18 years. @entity1274 varied between mild @entity2198 and profound (uni- and bilateral) @entity393 and was progressive in three @entity1 . Four @entity12697 @entity1 received cochlear implants for their severe @entity1274 . The cohort is small for genotype-phenotype correlations, but @entity1274 , especially the bilateral severe @entity393 , was only seen in @entity1 with a @entity9702 mutation. CONCLUSION: @entity12697 is characterized by dysmorphic @entity2169 and both @entity1274 . Audiological examinations are recommended in all @entity1 with @entity12697 .

title: @entity2169 and @entity393 in XXXX .

answer: @entity12697 :: (MESH:D009634,Disease) :: ['Noonan Syndrome']


abstract: OBJECTIVE: This is the first cohort in which @entity393 and @entity2169 in @entity12697 are described extensively. METHODS: Retrospective analysis of the otorhinolaryngological and clinical genetic data from 97 @entity12697 ( @entity12697 ) @entity1 . Forty-four @entity12697 @entity1 were seen by an otorhinolaryngologist for the analysis of @entity393 . In our cohort 80 of the 97 @entity1 were genetically tested. In 71 of these mutations were found: in 48 @entity1 a mutation in @entity9702 , in 10 @entity1 in @entity25941 , in 5 @entity1 in @entity25281 , in 5 @entity1 in @entity10242 , in 1 @entity1 in @entity29343 , in 1 @entity1 in @entity984 and in 1 @entity1 in @entity29740 . RESULTS: @entity2169 were reported in 75 @entity12697 @entity1 (77%). In 69 @entity1 the ears were low-set, 28 @entity1 had @entity717 , 14 @entity1 showed protruding ears and 18 had thickened helices. Hearing impairment was detected in 34 @entity12697 @entity1 . Nine @entity1 had @entity1274 , two a permanent conductive @entity393 , two other @entity1 had mixed @entity393 and 20 @entity1 had conductive @entity393 in the past, caused by @entity2346 media with effusion. Their temporary conductive @entity393 resolved between the ages of 2 and 18 years. @entity1274 varied between mild @entity2198 and profound (uni- and bilateral) @entity393 and was progressive in three @entity1 . Four @entity12697 @entity1 received cochlear implants for their severe @entity1274 . The cohort is small for genotype-phenotype correlations, but @entity1274 , especially the bilateral severe @entity393 , was only seen in @entity1 with a @entity9702 mutation. CONCLUSION: @entity12697 is characterized by dysmorphic @entity2169 and both @entity1274 . Audiological examinations are recommended in all @entity1 with @entity12697 .

title: XXXX and @entity393 in @entity12697 .

answer: @entity2169 :: (MESH:D004427,Disease) :: ['External ear anomalies']


abstract: OBJECTIVES: The aim was to test whether or not the marginal bone-level alterations of loaded zirconia implants are similar to the bone-level alterations of a grade 4 @entity702 one-piece dental implant. MATERIALS AND METHODS: In six @entity235 , all premolars and the first molars were extracted in the mandible. Four months later, three zirconia implants ( @entity72162 , VC, ZD) and a control @entity702 one-piece (STM) implant were randomly placed in each hemimandible and left for transmucosal healing (baseline). Six months later, CAD/CAM crowns were cemented. Sacrifice was scheduled at 6-month postloading. Digital X-rays were taken at implant placement, crowns insertion, and sacrifice. Marginal bone-level alterations were calculated, and intra- and intergroup comparisons performed adjusted by confounding factors. RESULTS: Implants were successfully placed. Until crown insertion, two implants were @entity174 (one VC, one ZD). At sacrifice, 5 more implants were (partly) @entity174 (one @entity72162 , four ZD), and one lost osseointegration (VC). No decementation of crowns occurred. All implant systems demonstrated a statistically significant (except VC) loss of marginal bone between baseline and crown insertion ranging from 0.29  mm (VC; P  =  0.116) to 0.80  mm (ZD; P  =  0.013). The estimated marginal @entity604 between baseline and 6  months of loading ranged between 0.19  mm ( @entity72162 ) and 1.11  mm (VC), being statistically significant for STM and VC only (P  <  0.05). The changes in marginal bone levels were statistically significantly different between zirconia implants and control implants (STM vs. @entity72162 P  =  0.007; vs. VC P  =  0.001; vs. ZD P  =  0.011). CONCLUSIONS: Zirconia implants were more prone to @entity174 prior to and after loading with implant-supported crowns compared to @entity702 implants. Individual differences and variability in the extent of the bone-level changes during the 12-month study period were found between the different implant types and materials.

title: Marginal bone-level alterations of loaded zirconia and XXXX dental implants: an experimental study in the @entity235 mandible.

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractured', 'fracture']

entities_list: @entity604 :: ('MESH:D016301', 'Disease') :: ['bone loss']

entities_list: @entity702 :: ('MESH:D014025', 'Chemical') :: ['titanium']

answer: @entity702 :: (MESH:D014025,Chemical) :: ['titanium']


abstract: OBJECTIVES: The aim was to test whether or not the marginal bone-level alterations of loaded zirconia implants are similar to the bone-level alterations of a grade 4 @entity702 one-piece dental implant. MATERIALS AND METHODS: In six @entity235 , all premolars and the first molars were extracted in the mandible. Four months later, three zirconia implants ( @entity72162 , VC, ZD) and a control @entity702 one-piece (STM) implant were randomly placed in each hemimandible and left for transmucosal healing (baseline). Six months later, CAD/CAM crowns were cemented. Sacrifice was scheduled at 6-month postloading. Digital X-rays were taken at implant placement, crowns insertion, and sacrifice. Marginal bone-level alterations were calculated, and intra- and intergroup comparisons performed adjusted by confounding factors. RESULTS: Implants were successfully placed. Until crown insertion, two implants were @entity174 (one VC, one ZD). At sacrifice, 5 more implants were (partly) @entity174 (one @entity72162 , four ZD), and one lost osseointegration (VC). No decementation of crowns occurred. All implant systems demonstrated a statistically significant (except VC) loss of marginal bone between baseline and crown insertion ranging from 0.29  mm (VC; P  =  0.116) to 0.80  mm (ZD; P  =  0.013). The estimated marginal @entity604 between baseline and 6  months of loading ranged between 0.19  mm ( @entity72162 ) and 1.11  mm (VC), being statistically significant for STM and VC only (P  <  0.05). The changes in marginal bone levels were statistically significantly different between zirconia implants and control implants (STM vs. @entity72162 P  =  0.007; vs. VC P  =  0.001; vs. ZD P  =  0.011). CONCLUSIONS: Zirconia implants were more prone to @entity174 prior to and after loading with implant-supported crowns compared to @entity702 implants. Individual differences and variability in the extent of the bone-level changes during the 12-month study period were found between the different implant types and materials.

title: Marginal bone-level alterations of loaded zirconia and @entity702 dental implants: an experimental study in the XXXX mandible.

answer: @entity235 :: (9615,Species) :: ['dog']


abstract: UNASSIGNED: Dialectical behaviour therapy (DBT)-informed skills training for @entity4225 ( @entity4225 ) aims at the development of specific emotion regulation skills in @entity1 , particularly with regard to the regulation of problematic anger. While the effects of dialectical behaviour skills training have been shown, their processes of change are rarely examined. Neacsiu, Rizvi and Linehan (2010) found that @entity1 's self-reported use of emotion regulation skills was a mediator of therapeutic change in these treatments; however, they found no effect for problematic anger. From an integrative perspective on anger (Pascual-Leone _ Greenberg, 2007; Pascual-Leone _ Paivio, 2013), there are several forms of anger, varying in their degree of therapeutic productivity. The present add-on randomized controlled trial included n   =   41 @entity1 with @entity4225 (n   =   21 DBT-informed skills training versus n   =   20 treatment as usual). The first study examined the outcome of the DBT-informed skills training encompassing basic components of training in mindfulness, distress tolerance, interpersonal effectiveness and emotion regulation. Results showed that symptom reduction was significantly greater in the DBT-informed skills training, compared with the treatment as usual. The second study used process assessment, for which all @entity1 completers underwent a 50-min-long psychological interview both early and late in treatment, which was rated using the Classification of Affective Meaning States. DBT-informed skills training produced increased levels of primary 'assertive' anger, as compared with the treatment as usual, whereas no effect was found for 'rejecting' secondary anger. Most importantly, we showed that changes in assertive anger mediated the reported symptom reduction, in particular in @entity1 's social roles. We discuss these results in the context of underlying mechanisms of change in DBT skills group treatments, in particular towards developing more productive forms of anger in this @entity1 population. Copyright    2015 John Wiley _ Sons, Ltd. KEY PRACTITIONER MESSAGE: A 20-session dialectical behaviour therapy (DBT)-informed skills training is a promising adjunct intervention for @entity1 with @entity4225 , in particular for reducing problems related to social role. Increases in assertive anger mediate the effects of DBT-informed skills training, whereas rejecting anger remains unchanged over the course of treatment. Short-term objectives for intervention might involve the specific increase of assertive anger in @entity4225 , by using DBT-informed skills training; long-term objectives for intervention might involve a specific decrease of rejecting anger in @entity4225 .

title: Assertive Anger Mediates Effects of Dialectical Behaviour-informed Skills Training for XXXX : A Randomized Controlled Trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'patients']

entities_list: @entity4225 :: ('MESH:D001883', 'Disease') :: ['borderline personality disorder', 'BPD']

answer: @entity4225 :: (MESH:D001883,Disease) :: ['Borderline Personality Disorder']


abstract: The extent of early resolution of major @entity1151 observed in 10 @entity1 after 24 hours of treatment with heparin was compared with that seen in 17 @entity1 after 24 hours of treatment with streptokinase. The @entity1 in the streptokinase group also received a loading dose of heparin and were treated with heparin by continuous infusion when their @entity556 time returned to normal levels. All had @entity120 . @entity1151 was classified as acute in the 10 @entity1 in the heparin group. Seven of these @entity1 showed no angiographic change, two showed slight improvement and one showed @entity5122 . There was a moderate and statistically insignificant fall in mean pulmonary arterial pressure and total pulmonary resistance. Fourteen of the 17 @entity1 who were studied before and after streptokinase were classified as acute and three as subacute progressive major @entity1151 . Eight showed marked angiographic improvement, four moderate and two slight angiographic improvement. There was a moderate and statistically significant fall in the mean pulmonary arterial pressure and pulmonary vascular resistance. In addition, all seven @entity1 in whom no angiographic improvement occurred during heparin therapy showed moderate or marked angiographic improvement after a further 24 hours of treatment with streptokinase. The results strongly suggest that streptokinase therapy accelerates thrombolysis in @entity1 with acute major @entity1151 .

title: Comparison of the effects of streptokinase and heparin on the early rate of resolution of major XXXX .

entities_list: @entity5122 :: ('MESH:C565430', 'Disease') :: ['angiographic deterioration']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['Pulmonary embolism', 'pulmonary embolism']

answer: @entity1151 :: (MESH:D011655,Disease) :: ['pulmonary embolism']


abstract: The Wolfram, or @entity19278 , syndrome consists of @entity2010 , @entity6 , @entity1952 , and @entity2319 . @entity6 usually occurs as the first manifestation of this syndrome, followed by the development of @entity1952 , @entity393 , and finally @entity2010 . We report on four cases with a review of the literature. The @entity6 occurring in these @entity1 is clinically indistinguishable from classic @entity6 . Two of three @entity1 continue to have measurable C-peptide secretion 8 yr after onset of @entity6 . Two of three @entity1 with @entity19278 had the HLA-DR2 antigen. Combining our cases with those described in the literature, 7 of 11 @entity1 have the HLA-DR2 antigen. The preponderance of the HLA-DR2 antigen in the @entity19278 is different from classic @entity1723 . This is further evidence of the genetic heterogeneity of @entity6 . Although the @entity19278 is rare, it should be considered in @entity6 @entity1 with unexplained @entity1952 and @entity393 or with @entity2011 and @entity4683 in the presence of adequate blood sugar control.

title: XXXX : report of four new cases and a review of literature.

entities_list: @entity1952 :: ('MESH:D009896', 'Disease') :: ['optic atrophy']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['type I diabetes mellitus', 'diabetic', 'diabetes', 'diabetes mellitus', 'Diabetes mellitus']

entities_list: @entity19278 :: ('MESH:D014929', 'Disease') :: ['DIDMOAD', 'Wolfram syndrome']

entities_list: @entity4683 :: ('MESH:D059606', 'Disease') :: ['polydipsia']

entities_list: @entity1723 :: ('MESH:D003922', 'Disease') :: ['type I diabetes']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss', 'neurosensory hearing loss']

entities_list: @entity2010 :: ('MESH:D003919', 'Disease') :: ['diabetes insipidus']

answer: @entity19278 :: (MESH:D014929,Disease) :: ['Wolfram syndrome']


abstract: UNASSIGNED: MicroRNA 26a ( @entity47695 ) has been reported to play functions in cellular differentiation, cell growth, cell apoptosis and @entity3 . However, the role of @entity47695 in transplant rejection has never been investigated. Full-thickness skin grafts 1 to 2 cm in diameter were obtained from the tail-skin CBA/J donor @entity19 and transplanted onto the back of wild-type C57BL/6 recipient @entity19 . Vectors encoding pre- @entity47695 (LV-26a) and an empty lentiviral vector (LV-Con) delivered approximately 2 * 10(7) transforming units of recombinant lentivirus were injected to @entity19 once through the tail vein. @entity47695 overexpression results in prolonged skin allograft survival (MST = 9.5 days in LV-Con @entity19 ; MST = 22 days in LV-26a @entity19 . P < 0.01) and promoted regulatory T cells (Tregs) expansion. The prolonged skin allograft survival induced by LV-26a was abrogated by depletion of Tregs with anti- @entity3783 antibodies. @entity47695 significantly promoted @entity1618 expression and suppressed the expression of @entity777 , @entity636 and IFN-y. Furthermore, @entity777 overexpression led to complete suppression of the @entity47695 -induced upregulation of @entity3744 . The prolonged allograft survival induced by LV- @entity47695 was also completely abrogated by @entity777 overexpression. In conclusion, @entity47695 prolongs skin allograft survival and promotes Tregs expansion in part through inhibition of @entity777 expression. This article is protected by copyright. All rights reserved.

title: MicroRNA 26a Prolongs Skin Allograft Survival and Promotes Regulatory T Cells Expansion in XXXX .

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: BACKGROUND: @entity344 is known as a risk factor for the development of the @entity1744 (post-infectious @entity1744 , @entity5377 ). The incidence of @entity5377 ranges between 3% and over 30% of @entity1 after @entity1902 . AIM: To perform a meta-analysis pools and report data concerning the relative risk (RR) of @entity5377 after @entity8527 . METHODS: Database search using Medline through PubMed, Scopus, EBM Reviews (Cochrane Database of Systematic Reviews) and PsycINFO was performed to identify relevant studies. Those that met the inclusion criteria were pooled. A random effects model (Mantel-Haenszel) was performed. RESULTS: Six eligible studies were found. In three of six studies, the authors reported a statistically significant association of @entity8527 and @entity5377 . The pooled RR was 3.35 (95% CI: 2.22-5.05) with a significant overall effect (P  <  0.00001). Overall @entity5377 incidence was 5.4% in @entity8527 subjects and 1.4% in healthy subjects. There was no significant heterogeneity within the pooled studies (I(2)   =  5%). Self-reported @entity8527 alone resulted in an over 1.5-fold RR for @entity5377 compared to laboratory-confirmed @entity8527 [RR 3.90 (95% CI: 2.35-6.49) vs. RR 2.42 (95% CI: 1.22-4.78)]. CONCLUSIONS: There is a strong association between travellers' @entity294 and post-infectious @entity1744 . Self-reports of exposure seem to result in a higher post-infectious @entity1744 occurrence than laboratory-confirmed cases of travellers' @entity294 , but further studies are needed to confirm this finding. Finally, potential influences of the selection of an appropriate study population on post-infectious @entity1744 epidemiology are discussed.

title: Systematic review with meta-analysis: post-infectious @entity1744 after travellers' XXXX .

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['Gastrointestinal infection']

entities_list: @entity1902 :: ('MESH:D005759', 'Disease') :: ['infectious gastroenteritis']

entities_list: @entity1744 :: ('MESH:D043183', 'Disease') :: ['irritable bowel syndrome']

answer: @entity294 :: (MESH:D003967,Disease) :: ['diarrhoea']


abstract: BACKGROUND: @entity344 is known as a risk factor for the development of the @entity1744 (post-infectious @entity1744 , @entity5377 ). The incidence of @entity5377 ranges between 3% and over 30% of @entity1 after @entity1902 . AIM: To perform a meta-analysis pools and report data concerning the relative risk (RR) of @entity5377 after @entity8527 . METHODS: Database search using Medline through PubMed, Scopus, EBM Reviews (Cochrane Database of Systematic Reviews) and PsycINFO was performed to identify relevant studies. Those that met the inclusion criteria were pooled. A random effects model (Mantel-Haenszel) was performed. RESULTS: Six eligible studies were found. In three of six studies, the authors reported a statistically significant association of @entity8527 and @entity5377 . The pooled RR was 3.35 (95% CI: 2.22-5.05) with a significant overall effect (P  <  0.00001). Overall @entity5377 incidence was 5.4% in @entity8527 subjects and 1.4% in healthy subjects. There was no significant heterogeneity within the pooled studies (I(2)   =  5%). Self-reported @entity8527 alone resulted in an over 1.5-fold RR for @entity5377 compared to laboratory-confirmed @entity8527 [RR 3.90 (95% CI: 2.35-6.49) vs. RR 2.42 (95% CI: 1.22-4.78)]. CONCLUSIONS: There is a strong association between travellers' @entity294 and post-infectious @entity1744 . Self-reports of exposure seem to result in a higher post-infectious @entity1744 occurrence than laboratory-confirmed cases of travellers' @entity294 , but further studies are needed to confirm this finding. Finally, potential influences of the selection of an appropriate study population on post-infectious @entity1744 epidemiology are discussed.

title: Systematic review with meta-analysis: post-infectious XXXX after travellers' @entity294 .

answer: @entity1744 :: (MESH:D043183,Disease) :: ['irritable bowel syndrome']


abstract: BACKGROUND: The release of cardiac biomarkers of @entity296 after transcatheter aortic valve replacement (TAVR) is common, but no data exist on @entity1 undergoing TAVR through a transaortic approach. We aimed to evaluate the incidence and prognostic significance of the increase in cardiac biomarkers in nontransfemoral TAVR candidates, comparing transaortic and transapical approaches. METHODS: After excluding @entity1 deemed suitable for transfemoral TAVR, 251 consecutive @entity1 (transaortic, 45; transapical, 206) were prospectively evaluated. @entity908 kinase-myocardial band and cardiac troponin T levels were measured at baseline and at 6, 12, 24, 48, and 72 hours after TAVR. Baseline and 6- to 12-month echocardiographic and clinical follow-up were performed. RESULTS: After TAVR, cardiac troponin T increased above the upper normal values in all @entity1 (peak value 0.64  g/L [IQR, 0.39 to 1.03  g/L]), whereas @entity908 kinase-myocardial band levels increased in 88% of @entity1 (transaortic 51%, transapical 96%, p < 0.001; peak value 20.1   g/L [interquartile range, 14.3 to 31.6  g/L]). Compared with the transaortic approach, the transapical approach was associated with a greater rise in both cardiac biomarkers (p < 0.001 for both), and a lesser improvement in left ventricular ejection fraction (p  = 0.058) and @entity6475 (p  = 0.039) at 6- to 12-month follow-up. Greater increases of cardiac troponin T levels were independently associated with 30-day and 1-year overall and cardiovascular mortality (p < 0.001 for all). A 15-fold rise in cardiac troponin T levels was the optimal threshold for determining poorer outcomes (p < 0.001). CONCLUSIONS: Periprocedural TAVR-related @entity296 in nontransfemoral candidates was demonstrated in all @entity1 , but the transapical approach was associated with significantly greater @entity296 compared with the transaortic approach. A higher degree of @entity296 translated into reduced left ventricular function improvement and lower early and midterm survival rates.

title: XXXX After Transaortic Versus  Transapical Transcatheter Aortic Valve  Replacement.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine', 'Creatine']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial injury']

entities_list: @entity6475 :: ('MESH:D013180', 'Disease') :: ['global longitudinal strain']

answer: @entity296 :: (MESH:D009202,Disease) :: ['Myocardial Injury']


abstract: PURPOSE: The purpose of this study was to evaluate the risks of second @entity5 and @entity65 associated with an optimized volumetric modulated arc therapy (VMAT) planning solution in a selected cohort of stage I/II @entity978 ( @entity978 ) @entity1 treated with either involved-node or involved-site radiation therapy in comparison with 3-dimensional conformal radiation therapy (3D-CRT). METHODS AND MATERIALS: Thirty-eight @entity1 (13 males and 25 females) were included. Disease extent was mediastinum alone (n=8, 21.1%); mediastinum plus unilateral neck (n=19, 50%); mediastinum plus bilateral neck (n=11, 29.9%). Prescription dose was 30 Gy in 2-Gy fractions. Only 5 @entity1 had mediastinal bulky disease at diagnosis (13.1%). Anteroposterior 3D-CRT was compared with a multiarc optimized VMAT solution. Lung, breast, and @entity259 risks were estimated by calculating a lifetime attributable risk (LAR), with a LAR ratio (LARVMAT-to-LAR3D-CRT) as a comparative measure. @entity1370 risks were estimated by calculating absolute excess risk (AER). RESULTS: The LAR ratio favored 3D-CRT for @entity2 induction risk in mediastinal alone (P=.004) and mediastinal plus unilateral neck (P=.02) presentations. LAR ratio for @entity0 was lower for VMAT in mediastinal plus bilateral neck presentations (P=.02), without differences for other sites. For @entity259 , no significant differences were observed, regardless of anatomical presentation. A significantly lower AER of cardiac (P=.038) and @entity340 (P<.0001) was observed for VMAT regardless of disease extent. CONCLUSIONS: In a cohort of @entity1 with favorable characteristics in terms of disease extent at diagnosis (large prevalence of nonbulky presentations without axillary involvement), optimized VMAT reduced @entity299 risk with comparable risks of @entity0 , with an increase in @entity2 induction probability. The results are however strongly influenced by the different anatomical presentations, supporting an individualized approach.

title: Optimized Volumetric Modulated Arc Therapy Versus 3D-CRT for Early Stage Mediastinal XXXX Without Axillary Involvement: A @entity5 and @entity299 Risk.

entities_list: @entity340 :: ('MESH:D006349', 'Disease') :: ['valvular diseases']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'thyroid and breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease']

entities_list: @entity978 :: ('MESH:D006689', 'Disease') :: ['HL', 'Hodgkin lymphoma']

entities_list: @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid cancer']

entities_list: @entity1370 :: ('MESH:D066126', 'Disease') :: ['Cardiac toxicity']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular diseases']

answer: @entity978 :: (MESH:D006689,Disease) :: ['Hodgkin Lymphoma']


abstract: PURPOSE: The purpose of this study was to evaluate the risks of second @entity5 and @entity65 associated with an optimized volumetric modulated arc therapy (VMAT) planning solution in a selected cohort of stage I/II @entity978 ( @entity978 ) @entity1 treated with either involved-node or involved-site radiation therapy in comparison with 3-dimensional conformal radiation therapy (3D-CRT). METHODS AND MATERIALS: Thirty-eight @entity1 (13 males and 25 females) were included. Disease extent was mediastinum alone (n=8, 21.1%); mediastinum plus unilateral neck (n=19, 50%); mediastinum plus bilateral neck (n=11, 29.9%). Prescription dose was 30 Gy in 2-Gy fractions. Only 5 @entity1 had mediastinal bulky disease at diagnosis (13.1%). Anteroposterior 3D-CRT was compared with a multiarc optimized VMAT solution. Lung, breast, and @entity259 risks were estimated by calculating a lifetime attributable risk (LAR), with a LAR ratio (LARVMAT-to-LAR3D-CRT) as a comparative measure. @entity1370 risks were estimated by calculating absolute excess risk (AER). RESULTS: The LAR ratio favored 3D-CRT for @entity2 induction risk in mediastinal alone (P=.004) and mediastinal plus unilateral neck (P=.02) presentations. LAR ratio for @entity0 was lower for VMAT in mediastinal plus bilateral neck presentations (P=.02), without differences for other sites. For @entity259 , no significant differences were observed, regardless of anatomical presentation. A significantly lower AER of cardiac (P=.038) and @entity340 (P<.0001) was observed for VMAT regardless of disease extent. CONCLUSIONS: In a cohort of @entity1 with favorable characteristics in terms of disease extent at diagnosis (large prevalence of nonbulky presentations without axillary involvement), optimized VMAT reduced @entity299 risk with comparable risks of @entity0 , with an increase in @entity2 induction probability. The results are however strongly influenced by the different anatomical presentations, supporting an individualized approach.

title: Optimized Volumetric Modulated Arc Therapy Versus 3D-CRT for Early Stage Mediastinal @entity978 Without Axillary Involvement: A @entity5 and XXXX Risk.

answer: @entity299 :: (MESH:D006331,Disease) :: ['Heart Disease']


abstract: PURPOSE: The purpose of this study was to evaluate the risks of second @entity5 and @entity65 associated with an optimized volumetric modulated arc therapy (VMAT) planning solution in a selected cohort of stage I/II @entity978 ( @entity978 ) @entity1 treated with either involved-node or involved-site radiation therapy in comparison with 3-dimensional conformal radiation therapy (3D-CRT). METHODS AND MATERIALS: Thirty-eight @entity1 (13 males and 25 females) were included. Disease extent was mediastinum alone (n=8, 21.1%); mediastinum plus unilateral neck (n=19, 50%); mediastinum plus bilateral neck (n=11, 29.9%). Prescription dose was 30 Gy in 2-Gy fractions. Only 5 @entity1 had mediastinal bulky disease at diagnosis (13.1%). Anteroposterior 3D-CRT was compared with a multiarc optimized VMAT solution. Lung, breast, and @entity259 risks were estimated by calculating a lifetime attributable risk (LAR), with a LAR ratio (LARVMAT-to-LAR3D-CRT) as a comparative measure. @entity1370 risks were estimated by calculating absolute excess risk (AER). RESULTS: The LAR ratio favored 3D-CRT for @entity2 induction risk in mediastinal alone (P=.004) and mediastinal plus unilateral neck (P=.02) presentations. LAR ratio for @entity0 was lower for VMAT in mediastinal plus bilateral neck presentations (P=.02), without differences for other sites. For @entity259 , no significant differences were observed, regardless of anatomical presentation. A significantly lower AER of cardiac (P=.038) and @entity340 (P<.0001) was observed for VMAT regardless of disease extent. CONCLUSIONS: In a cohort of @entity1 with favorable characteristics in terms of disease extent at diagnosis (large prevalence of nonbulky presentations without axillary involvement), optimized VMAT reduced @entity299 risk with comparable risks of @entity0 , with an increase in @entity2 induction probability. The results are however strongly influenced by the different anatomical presentations, supporting an individualized approach.

title: Optimized Volumetric Modulated Arc Therapy Versus 3D-CRT for Early Stage Mediastinal @entity978 Without Axillary Involvement: A XXXX and @entity299 Risk.

answer: @entity5 :: (MESH:D009369,Disease) :: ['Comparison of Second Cancers']


abstract: @entity4053 results in a reduction in cardiac baroreflex sensitivity and a shift in the baroreflex working range to higher heart rates. This effect is mediated, in part, by the carotid chemoreceptors. Therefore, we hypothesized @entity4053 -mediated changes in baroreflex control of heart rate would be blunted in carotid body-resected @entity1 when compared with healthy controls. Five @entity1 with bilateral carotid body resection for @entity5 and 10 healthy controls completed a 180-minute @entity1717 , hypoglycemic (   3.3 mmol/L) clamp. Changes in heart rate, blood pressure, and spontaneous cardiac baroreflex sensitivity were assessed. Baseline baroreflex sensitivity was not different between groups (P>0.05). @entity4053 resulted in a reduction in baroreflex sensitivity in both the groups (main effect of time, P<0.01) and responses were lower in resected @entity1 when compared with controls (main effect of group, P<0.05). @entity4053 resulted in large reductions in systolic (-17  7 mm Hg) and mean (-14  5 mm Hg) blood pressure in resected @entity1 that were not observed in controls (interaction of group and time, P<0.05). Despite lower blood pressures, increases in heart rate with @entity4053 were blunted in resected @entity1 (interaction of group and time, P<0.01). Major novel findings from this study demonstrate that intact carotid chemoreceptors are essential for increasing heart rate and maintaining arterial blood pressure during @entity4053 in @entity1 . These data support a contribution of the carotid chemoreceptors to blood pressure control and highlight the potential widespread effects of carotid body resection in @entity1 .

title: Effect of bilateral carotid body resection on cardiac baroreflex control of blood pressure during XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'patients']

entities_list: @entity1717 :: ('MESH:D044903', 'Disease') :: ['hyperinsulinemic']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['glomus tumors']

entities_list: @entity4053 :: ('MESH:D007003', 'Disease') :: ['Hypoglycemia', 'hypoglycemia']

answer: @entity4053 :: (MESH:D007003,Disease) :: ['hypoglycemia']


abstract: Purpose: To evaluate ultrasonographic accuracy in the differentiation of a bezoar from feces in a @entity1744 showing feces-like material just proximal to the transitional zone in abdominal computed tomography (CT). Methods: This study included 14 @entity1 who showed feces-like material just proximal to the transitional zone, among 302 @entity1 diagnosed with @entity1744 on abdominal CT. Ultrasonographic findings such as posterior acoustic shadow and twinkling artifact were considered the diagnostic signs of a bezoar. The diagnostic performance was assessed by comparing these with a clinical diagnosis, which was confirmed by surgery or symptomatic improvement. Results: Among the 14 @entity1 , seven were ultrasonographically diagnosed as having a bezoar, and five of them were surgically diagnosed as having a phytobezoar. Two @entity1 diagnosed as having a bezoar showed complete symptomatic improvement before surgery. The seven @entity1 for whom having a bezoar was ruled out ultrasonographically conservatively treated. Among them, six @entity1 showed symptomatic improvement, suggesting the absence of a bezoar. The seventh @entity1 was confirmed as adhesive band-induced @entity3885 . In all @entity1 , the ultrasonographic diagnosis agreed with the clinically confirmed diagnosis. Conclusion: Ultrasonography is an accurate method for the differential diagnosis of feces-like material just proximal to the transitional zone in abdominal CT. It can help radiologists to quickly and easily diagnose a bezoar.

title: Ultrasonographic differentiation of bezoar from feces in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1744 :: ('MESH:D043183', 'Disease') :: ['small bowel obstruction']

entities_list: @entity3885 :: ('MESH:D008173', 'Disease') :: ['obstruction']

answer: @entity1744 :: (MESH:D043183,Disease) :: ['small bowel obstruction']


abstract: UNASSIGNED: Glutamatergic neurotransmission is evolutionarily conserved across animal phyla. A major class of @entity3264 receptors are the metabotropic @entity3264 receptors (mGluRs). In @entity2199 three mGluR genes @entity72163 , @entity72164 and @entity72165 are organised into three sub-groups, similar to their @entity1 counterparts. Cellular reporters identified expression of the mgls in the nervous system of @entity2199 and overlapping expression in the pharyngeal microcircuit that controls pharyngeal muscle activity and feeding behaviour. The overlapping expression of mgls within this circuit allowed investigation of receptor signalling per se and in the context of receptor interactions within a neural network that regulates feeding. We utilized the pharmacological manipulation of neuronally regulated pumping of the pharyngeal muscle in wild type and mutants to investigate mgl function. This defined a net @entity72163 dependent inhibition of pharyngeal pumping which is modulated by @entity72165 excitation. Optogenetic activation of the pharyngeal glutamatergic inputs combined with electrophysiological recordings from the isolated pharyngeal preparations provided further evidence for a presynaptic @entity72163 dependent regulation of pharyngeal activity. Analysis of @entity72163 , @entity72164 and @entity72165 mutant feeding behaviour in the intact organism after acute food removal identified a significant role for @entity72163 in the regulation of an adaptive feeding response. Our data describes the molecular and cellular organisation of @entity72163 , @entity72164 and @entity72165 . Pharmacological analysis identified that in these paradigms @entity72163 and @entity72165 , but not @entity72164 , can modulate the pharyngeal microcircuit. Behavioural analysis identified @entity72163 as a significant determinant of the @entity3264 -dependent modulation of feeding, further highlighting the significance of mGluRs in complex @entity2199 behaviour.

title: Metabotropic @entity3264 receptors: modulators of context-dependent feeding behaviour in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian']

answer: @entity2199 :: (6239,Species) :: ['C. elegans']